Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Schizophrenia

Free Subscription Articles published in Br J Psychiatry Retrieve available abstracts of 74 articles: HTML format

Single Articles

January 2025
1. KANG S, Yang JS, Yun BH, Gelaye B, et al
   Antipsychotic continuation during pregnancy and risk of postpartum relapse in women with schizophrenia: nationwide register-based study.
   Br J Psychiatry. 2025 Jan 10:1-8. doi: 10.1192/bjp.2024.
   PubMed     Abstract available
   
   
   
2. WANG F, Liu Z, Wang J, Li X, et al
   Aberrant controllability of functional connectome during working memory tasks in patients with schizophrenia and unaffected siblings.
   Br J Psychiatry. 2025 Jan 7:1-10. doi: 10.1192/bjp.2024.
   PubMed     Abstract available
   
   
   December 2024
3. ZHOU J, Millier A, Aballea S, Francois C, et al
   Cost-effectiveness of ten commonly used antipsychotics in first-episode schizophrenia in the UK: economic evaluation based on a de novo discrete event simulation model.
   Br J Psychiatry. 2024 Dec 26:1-8. doi: 10.1192/bjp.2024.
   PubMed     Abstract available
   
   
   
4. SMITH KA, Boyce N, Chevance A, Chiocchia V, et al
   Triangulating evidence from the GALENOS living systematic review on trace amine-associated receptor 1 (TAAR1) agonists in psychosis.
   Br J Psychiatry. 2024 Dec 23:1-9. doi: 10.1192/bjp.2024.
   PubMed     Abstract available
   
   
   
5. NAUGHTON S, McGinty G, Duffy N, Marshall D, et al
   Intervening early across the lifespan: going beyond youth-focused psychosis care to meet the needs of women.
   Br J Psychiatry. 2024 Dec 4:1-3. doi: 10.1192/bjp.2024.
   PubMed     Abstract available
   
   
   
6. YANG LH, Grivel MM, Blasco D, Girgis RR, et al
   Parsing stigma's relationship with the psychosocial functioning of youth identified as at clinical high risk for psychosis: evaluating whether symptom stigma or labelling stigma is stronger.
   Br J Psychiatry. 2024 Dec 4:1-9. doi: 10.1192/bjp.2024.
   PubMed     Abstract available
   
   
   
7. CHESNEY E, Reilly TJ, Scott F, Slimani I, et al
   Psychosis associated with cannabis withdrawal: systematic review and case series.
   Br J Psychiatry. 2024 Dec 3:1-12. doi: 10.1192/bjp.2024.
   PubMed     Abstract available
   
   
   November 2024
8. GREENWOOD K, Jones C, Yaziji N, Healey A, et al
   The Early Youth Engagement (EYE-2) intervention in first-episode psychosis services: pragmatic cluster randomised controlled trial and cost-effectiveness evaluation.
   Br J Psychiatry. 2024 Nov 25:1-9. doi: 10.1192/bjp.2024.
   PubMed     Abstract available
   
   
   
9. TREUR JL, Thijssen AB, Smit DJA, Tadros R, et al
   Associations of schizophrenia with arrhythmic disorders and electrocardiogram traits: genetic exploration of population samples.
   Br J Psychiatry. 2024 Nov 8:1-9. doi: 10.1192/bjp.2024.
   PubMed     Abstract available
   
   
   
10. HALL J
    Schizophrenia - new treatments soon.
    Br J Psychiatry. 2024 Nov 8:1-2. doi: 10.1192/bjp.2024.
    PubMed     Abstract available
    
    
    
11. TESLI N, Vaskinn A
    Violence and schizophrenia: let us take a deep breath and gain a meta-perspective.
    Br J Psychiatry. 2024;225:508-509.
    PubMed    
    
    
    October 2024
12. YANG JS, Kang S, Kim K, Tsai AC, et al
    Breast cancer risk among women with schizophrenia and association with duration of antipsychotic use: population-based cohort study in South Korea.
    Br J Psychiatry. 2024 Oct 31:1-7. doi: 10.1192/bjp.2024.
    PubMed     Abstract available
    
    
    
13. NICHOLLS D, Budd J, Nunn P, French P, et al
    Investigating inequalities in patient outcomes for first-episode psychosis.
    Br J Psychiatry. 2024 Oct 10:1-7. doi: 10.1192/bjp.2024.
    PubMed     Abstract available
    
    
    September 2024
14. JIANG Y, Chang X, Feng J
    Towards a unified theory of the aetiology of schizophrenia.
    Br J Psychiatry. 2024 Sep 23:1-3. doi: 10.1192/bjp.2024.
    PubMed     Abstract available
    
    
    
15. FERNANDEZ-EGEA E, Flanagan RJ, Taylor D, Gaughran F, et al
    Mortality associated with clozapine: what is the evidence?
    Br J Psychiatry. 2024;225:357-359.
    PubMed     Abstract available
    
    
    August 2024
16. LIU R, Li D, Ma Y, Tang L, et al
    Air pollutants, genetic susceptibility and the risk of schizophrenia: large prospective study.
    Br J Psychiatry. 2024 Aug 9:1-9. doi: 10.1192/bjp.2024.
    PubMed     Abstract available
    
    
    
17. KIKUCHI Y, Kurosawa M, Sakata M, Takahashi Y, et al
    Effects of titration speed, gender, obesity and concomitant medications on the risk and onset time of clozapine-associated fever among Japanese patients with schizophrenia: retrospective review of charts from 21 hospitals.
    Br J Psychiatry. 2024 Aug 6:1-7. doi: 10.1192/bjp.2024.
    PubMed     Abstract available
    
    
    
18. FAROOQ S, Hattle M, Kingstone T, Ajnakina O, et al
    Development and initial evaluation of a clinical prediction model for risk of treatment resistance in first-episode psychosis: Schizophrenia Prediction of Resistance to Treatment (SPIRIT).
    Br J Psychiatry. 2024 Aug 5:1-10. doi: 10.1192/bjp.2024.
    PubMed     Abstract available
    
    
    
19. SHERGILL SS, Meshreky KM
    Towards a unified theory of the aetiology of schizophrenia: commentary, Shergill et al.
    Br J Psychiatry. 2024 Aug 5:1-2. doi: 10.1192/bjp.2024.
    PubMed    
    
    
    
20. KUMARI V
    Towards a unified theory of the aetiology of schizophrenia: commentary, Kumari.
    Br J Psychiatry. 2024;225:341-342.
    PubMed    
    
    
    July 2024
21. HUANG ML, Wei LC
    Psychological framework to understand interpersonal violence by forensic patients with psychosis: commentary, Huang & Wei.
    Br J Psychiatry. 2024 Jul 31:1. doi: 10.1192/bjp.2024.
    PubMed    
    
    
    May 2024
22. CHEN PH, Tsai SY, Chen PY, Pan CH, et al
    Lipid-modifying agents and risk of all-cause, natural and suicide mortality in schizophrenia: nationwide cohort study.
    Br J Psychiatry. 2024 May 16:1-9. doi: 10.1192/bjp.2024.
    PubMed     Abstract available
    
    
    
23. FREEMAN D
    Developing psychological treatments for psychosis.
    Br J Psychiatry. 2024;224:147-149.
    PubMed     Abstract available
    
    
    
24. FERNANDEZ-EGEA E, Chen S, Sanguesa E, Gasso P, et al
    The role of psychosis and clozapine load in excessive checking in treatment-resistant schizophrenia: longitudinal observational study.
    Br J Psychiatry. 2024;224:164-169.
    PubMed     Abstract available
    
    
    April 2024
25. QI R, Qureshi M, Gire N, Chaudhry IB, et al
    Ethnic density and first episode psychosis in the British Pakistani population: findings from the East Lancashire Early Intervention Service.
    Br J Psychiatry. 2024 Apr 18:1-6. doi: 10.1192/bjp.2024.
    PubMed     Abstract available
    
    
    March 2024
26. BONIVENTO C, Kambeitz-Ilankovic L, Maggioni E, Borgwardt S, et al
    Neurocognitive skills and vulnerability for psychosis in depression and across the psychotic spectrum: findings from the PRONIA Consortium - CORRIGENDUM.
    Br J Psychiatry. 2024 Mar 18:1. doi: 10.1192/bjp.2024.
    PubMed    
    
    
    February 2024
27. HASSIOTIS A, Noor M, Bebbington P, Ali A, et al
    Borderline intellectual functioning and psychosis: Adult Psychiatric Morbidity Survey evidence - CORRIGENDUM.
    Br J Psychiatry. 2024 Feb 13:1. doi: 10.1192/bjp.2024.
    PubMed    
    
    
    January 2024
28. MCCUTCHEON RA, Cannon A, Parmer S, Howes OD, et al
    How to classify antipsychotics: time to ditch dichotomies?
    Br J Psychiatry. 2024;224:20-25.
    PubMed     Abstract available
    
    
    November 2023
29. SAHIN D, Kambeitz-Ilankovic L, Wood S, Dwyer D, et al
    Algorithmic fairness in precision psychiatry: analysis of prediction models in individuals at clinical high risk for psychosis.
    Br J Psychiatry. 2023 Nov 8:1-11. doi: 10.1192/bjp.2023.
    PubMed     Abstract available
    
    
    October 2023
30. LAMBE S, Cooper K, Fazel S, Freeman D, et al
    Psychological framework to understand interpersonal violence by forensic patients with psychosis.
    Br J Psychiatry. 2023 Oct 20:1-8. doi: 10.1192/bjp.2023.
    PubMed     Abstract available
    
    
    
31. KOHLER-FORSBERG O, Ge F, Hauksdottir A, Thordardottir EB, et al
    Adverse childhood experiences and psychological functioning among women with schizophrenia or bipolar disorder: population-based study.
    Br J Psychiatry. 2023 Oct 18:1-7. doi: 10.1192/bjp.2023.
    PubMed     Abstract available
    
    
    
32. BONIVENTO C, Kambeitz-Ilankovic L, Maggioni E, Borgwardt S, et al
    Neurocognitive skills and vulnerability for psychosis in depression and across the psychotic spectrum: findings from the PRONIA Consortium.
    Br J Psychiatry. 2023;223:485-492.
    PubMed     Abstract available
    
    
    August 2023
33. JIN H, Kolawole O, Wang Z
    Cost-effectiveness analysis of physical activity interventions for people with schizophrenia or bipolar disorder: systematic review.
    Br J Psychiatry. 2023;223:362-376.
    PubMed     Abstract available
    
    
    
34. KELLEHER I
    Author's Reply. RE: Psychosis prediction 2.0: why child and adolescent mental health services should be a key focus for schizophrenia and bipolar disorder prevention research.
    Br J Psychiatry. 2023;223:394-395.
    PubMed    
    
    
    
35. GRIFFITHS SL, Brown L, Kirkbride JB
    RE: Psychosis prediction 2.0: why child and adolescent mental health services should be a key focus for schizophrenia and bipolar disorder prevention research.
    Br J Psychiatry. 2023;223:394.
    PubMed    
    
    
    July 2023
36. FERNANDEZ-EGEA E, Mucci A, Lee J, Kirkpatrick B, et al
    A new era for the negative symptoms of schizophrenia.
    Br J Psychiatry. 2023;223:269-270.
    PubMed     Abstract available
    
    
    
37. AYMERICH C, Catalan A, Salazar de Pablo G
    RE: Longitudinal effect of clozapine-associated sedation on motivation in schizophrenia: naturalistic longitudinal study.
    Br J Psychiatry. 2023;223:336.
    PubMed    
    
    
    
38. KIRKPATRICK B, Luther L, Strauss GP
    Negative symptoms in the clinic: we treat what we can describe.
    Br J Psychiatry. 2023;223:271-272.
    PubMed     Abstract available
    
    
    
39. WOLPE N, Chen S, Kirkpatrick B, Jones PB, et al
    Author's Reply. RE: Longitudinal effect of clozapine-associated sedation on motivation in schizophrenia: naturalistic longitudinal study.
    Br J Psychiatry. 2023;223:336-337.
    PubMed    
    
    
    
40. CHEN EYH, Wong SMY, Hui CLM, Suen YN, et al
    The emergence of primary negative symptoms: relevance of timing?
    Br J Psychiatry. 2023;223:280-281.
    PubMed     Abstract available
    
    
    June 2023
41. HOWES O, Fusar-Poli P, Osugo M
    Treating negative symptoms of schizophrenia: current approaches and future perspectives.
    Br J Psychiatry. 2023 Jun 5:1-4. doi: 10.1192/bjp.2023.
    PubMed     Abstract available
    
    
    
42. BYNG R, Creanor S, Jones B, Hosking J, et al
    The effectiveness of a primary care-based collaborative care model to improve quality of life in people with severe mental illness: PARTNERS2 cluster randomised controlled trial.
    Br J Psychiatry. 2023;222:246-256.
    PubMed     Abstract available
    
    
    
43. NORTHWOOD K, Pearson E, Arnautovska U, Kisely S, et al
    Optimising plasma clozapine levels to improve treatment response: an individual patient data meta-analysis and receiver operating characteristic curve analysis.
    Br J Psychiatry. 2023;222:241-245.
    PubMed     Abstract available
    
    
    May 2023
44. GALDERISI S, Kaiser S
    The pathophysiology of negative symptoms of schizophrenia: main hypotheses and open challenges.
    Br J Psychiatry. 2023 May 26:1-3. doi: 10.1192/bjp.2023.
    PubMed     Abstract available
    
    
    
45. PENADES R, Wykes T
    Use of cognitive remediation to treat negative symptoms in schizophrenia: is it time yet?
    Br J Psychiatry. 2023 May 17:1-2. doi: 10.1192/bjp.2023.
    PubMed     Abstract available
    
    
    
46. SALAZAR DE PABLO G, Catalan A, Vaquerizo Serrano J, Pedruzo B, et al
    Negative symptoms in children and adolescents with early-onset psychosis and at clinical high-risk for psychosis: systematic review and meta-analysis.
    Br J Psychiatry. 2023 May 17:1-13. doi: 10.1192/bjp.2022.
    PubMed     Abstract available
    
    
    March 2023
47. CELLA M, Roberts S, Pillny M, Riehle M, et al
    Psychosocial and behavioural interventions for the negative symptoms of schizophrenia: a systematic review of efficacy meta-analyses.
    Br J Psychiatry. 2023 Mar 15:1-11. doi: 10.1192/bjp.2023.
    PubMed     Abstract available
    
    
    January 2023
48. KELLEHER I
    Psychosis prediction 2.0: why child and adolescent mental health services should be a key focus for schizophrenia and bipolar disorder prevention research.
    Br J Psychiatry. 2023 Jan 12:1-3. doi: 10.1192/bjp.2022.
    PubMed     Abstract available
    
    
    
49. WOLPE N, Chen S, Kirkpatrick B, Jones PB, et al
    Longitudinal effect of clozapine-associated sedation on motivation in schizophrenia: naturalistic longitudinal study.
    Br J Psychiatry. 2023 Jan 10:1-3. doi: 10.1192/bjp.2022.
    PubMed     Abstract available
    
    
    
50. O'BRIEN KJ, Ered A, Korenic SA, Olino TM, et al
    Childhood trauma, perceived stress and anhedonia in individuals at clinical high risk for psychosis: multigroup mediation analysis.
    Br J Psychiatry. 2023 Jan 5:1-7. doi: 10.1192/bjp.2022.
    PubMed     Abstract available
    
    
    December 2022
51. AHANGARI M, Bustamante D, Kirkpatrick R, Nguyen TH, et al
    Relationship between polygenic risk scores and symptom dimensions of schizophrenia and schizotypy in multiplex families with schizophrenia.
    Br J Psychiatry. 2022 Dec 12:1-8. doi: 10.1192/bjp.2022.
    PubMed     Abstract available
    
    
    
52. IKKOS G, Stanghellini G
    Sensibility and schizophrenia: Wilhelm Waiblinger on Friedrich Holderlin's life, poetry and madness - psychiatry in literature.
    Br J Psychiatry. 2022;221:739.
    PubMed    
    
    
    
53. BUTLER E, Pillinger T, Brown K, Borgan F, et al
    Real-world clinical and cost-effectiveness of community clozapine initiation: mirror cohort study.
    Br J Psychiatry. 2022;221:740-747.
    PubMed     Abstract available
    
    
    November 2022
54. WATSON AJ, Harrison L, Preti A, Wykes T, et al
    Cognitive trajectories following onset of psychosis: a meta-analysis - CORRIGENDUM.
    Br J Psychiatry. 2022 Nov 14:1. doi: 10.1192/bjp.2022.
    PubMed    
    
    
    September 2022
55. WATSON AJ, Harrison L, Preti A, Wykes T, et al
    Cognitive trajectories following onset of psychosis: a meta-analysis.
    Br J Psychiatry. 2022 Sep 23:1-8. doi: 10.1192/bjp.2022.
    PubMed     Abstract available
    
    
    August 2022
56. LAHTEENVUO M, Luykx JJ, Taipale H, Mittendorfer-Rutz E, et al
    Associations between antipsychotic use, substance use and relapse risk in patients with schizophrenia: real-world evidence from two national cohorts.
    Br J Psychiatry. 2022 Aug 25:1-8. doi: 10.1192/bjp.2022.
    PubMed     Abstract available
    
    
    July 2022
57. FLEETWOOD K, Wild SH, Smith DJ, Mercer SW, et al
    Association of severe mental illness with stroke outcomes and process-of-care quality indicators: nationwide cohort study.
    Br J Psychiatry. 2022;221:394-401.
    PubMed     Abstract available
    
    
    May 2022
58. CURTIS D
    Identification of specific genes involved in schizophrenia aetiology - what difference does it make? - CORRIGENDUM.
    Br J Psychiatry. 2022 May 23:1. doi: 10.1192/bjp.2022.
    PubMed    
    
    
    April 2022
59. CURTIS D
    Identification of specific genes involved in schizophrenia aetiology - what difference does it make?
    Br J Psychiatry. 2022 Apr 6:1-3. doi: 10.1192/bjp.2021.
    PubMed     Abstract available
    
    
    February 2022
60. ANTONUCCI LA, Penzel N, Sanfelici R, Pigoni A, et al
    Using combined environmental-clinical classification models to predict role functioning outcome in clinical high-risk states for psychosis and recent-onset depression.
    Br J Psychiatry. 2022 Feb 14:1-17. doi: 10.1192/bjp.2022.
    PubMed     Abstract available
    
    
    
61. CUI Y, Li C, Liu B, Sui J, et al
    Consistent brain structural abnormalities and multisite individualised classification of schizophrenia using deep neural networks.
    Br J Psychiatry. 2022 Feb 11:1-8. doi: 10.1192/bjp.2022.
    PubMed     Abstract available
    
    
    January 2022
62. LEE R, Leighton SP, Thomas L, Gkoutos GV, et al
    Prediction models in first-episode psychosis: systematic review and critical appraisal.
    Br J Psychiatry. 2022 Jan 24:1-13. doi: 10.1192/bjp.2021.
    PubMed     Abstract available
    
    
    December 2021
63. XI YB, Wu XS, Cui LB, Bai LJ, et al
    Neuroimaging-based brain-age prediction of first-episode schizophrenia and the alteration of brain age after early medication.
    Br J Psychiatry. 2021 Dec 2:1-8. doi: 10.1192/bjp.2021.
    PubMed     Abstract available
    
    
    
64. BAKER SJ, Jackson M, Jongsma H, Saville CWN, et al
    The ethnic density effect in psychosis: a systematic review and multilevel meta-analysis.
    Br J Psychiatry. 2021;219:632-643.
    PubMed     Abstract available
    
    
    
65. BHUI K, Halvorsrud K, Mooney R, Hosang GM, et al
    Is psychosis a syndemic manifestation of historical and contemporary adversity? Findings from UK Biobank.
    Br J Psychiatry. 2021;219:686-694.
    PubMed     Abstract available
    
    
    
66. ELLETT L, Chadwick P
    Recommendations for monitoring and reporting harm in mindfulness for psychosis research.
    Br J Psychiatry. 2021;219:629-631.
    PubMed     Abstract available
    
    
    July 2021
67. MCDONALD K, Ding T, Ker H, Dliwayo TR, et al
    Using epidemiological evidence to forecast population need for early treatment programmes in mental health: a generalisable Bayesian prediction methodology applied to and validated for first-episode psychosis in England.
    Br J Psychiatry. 2021;219:383-391.
    PubMed     Abstract available
    
    
    
68. VAN DER MEER L, Kaiser S, Castelein S
    Negative symptoms in schizophrenia: reconsidering evidence and focus in clinical trials.
    Br J Psychiatry. 2021;219:359-360.
    PubMed     Abstract available
    
    
    
69. CASTELEIN S, Timmerman ME, van der Gaag M, Visser E, et al
    Clinical, societal and personal recovery in schizophrenia spectrum disorders across time: states and annual transitions.
    Br J Psychiatry. 2021;219:401-408.
    PubMed     Abstract available
    
    
    
70. ZHU Y, Wang S, Gong X, Edmiston EK, et al
    Associations between hemispheric asymmetry and schizophrenia-related risk genes in people with schizophrenia and people at a genetic high risk of schizophrenia.
    Br J Psychiatry. 2021;219:392-400.
    PubMed     Abstract available
    
    
    
71. BHATTACHERJEE S, Young A, Ahuja N, Allen S, et al
    Should intramuscular clozapine be adopted into mainstream clinical practice?
    Br J Psychiatry. 2021;219:357-358.
    PubMed     Abstract available
    
    
    May 2021
72. SISKIND D, Orr S, Sinha S, Yu O, et al
    Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis.
    Br J Psychiatry. 2021 May 11:1-6. doi: 10.1192/bjp.2021.
    PubMed     Abstract available
    
    
    October 2020
73. FOND G, Pauly V, Bege T, Orleans V, et al
    Trauma-related mortality of patients with severe psychiatric disorders: population-based study from the French national hospital database.
    Br J Psychiatry. 2020;217:568-574.
    PubMed     Abstract available
    
    
    May 2020
74. OHI K, Shimada T, Kataoka Y, Yasuyama T, et al
    Genetic correlations between subcortical brain volumes and psychiatric disorders.
    Br J Psychiatry. 2020;216:280-283.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Schizophrenia is free of charge.